First in-human, intracisternal dosing of RGX-111, an investigational AAV gene therapy, for a 21-month-old child with mucopolysaccharidosis type I (MPS I): 3.5 year follow-upRaymond Wang, Laura Rosa Pisani, Michelle Gilmor et al.|Molecular Genetics and Metabolism|2024Cited by 1
Audiology assessment of participants in CAMPSIITE™, a phase I/II/III study of RGX-121 in neuronopathic MPS IINidal Boulos, Paulo Falabella, Patricia Roush et al.|Molecular Genetics and Metabolism|2024Cited by 0
Audiology assessment of participants in CAMPSIITE®, a phase I/II/III study of investigational RGX-121 in neuronopathic MPS IINidal Boulos, Paulo Falabella, Dawn Phillips et al.|Molecular Genetics and Metabolism|2025Cited by 0
First-in-human intracisternal dosing of RGX-111 in severe MPS I is well tolerated and generates sustained neurodevelopment without HSCTRaymond Wang, Laura Rosa Pisani, Nina Movsesyan et al.|Molecular Therapy|2026Cited by 0